Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Yogurt study probes how friendly bacteria survive the gut

NCT ID NCT06799364

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at whether eating fermented dairy products with three types of Bifidobacterium (with or without prebiotic fibers) for 28 days changes the variety of gut bacteria in healthy people aged 45 to 60. 182 participants ate either a test yogurt or a regular yogurt. The goal was to see if the added bacteria survive digestion and boost gut diversity. This was an observation study, not a treatment for any disease.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

182 people

The number who actually took part.

Started

Feb 2025

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 60 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and female subjects aged between 45 and 60 years old. 2. BMI between 18.5 kg/m2 and 30 kg/m2. 3. Subjects who are overtly healthy as determined by the investigator. 4. Willing and/or able to: * Speak and read in French, * Collect, store and transport their faecal samples themselves, * Consume the study products twice per day for 28 consecutive days and not to consume any fermented dairy products during the entire study (other than the study products) as well as any probiotic, prebiotic or synbiotic supplements during the entire study. * Complete the electronic Patient Reported Outcomes (ePRO) using their own digital device having access to internet. 5. Willing to limit alcohol consumption and not to smoke or consume any soft or hard drug during the study. 6. Having access to adequate space to store the investigational products in their own fridge at home. 7. Having regular bowel movements. 8. Signed written informed consent by the participant. 9. Female subjects must either be postmenopausal for at least 12 months or have undergone specific surgical procedures resulting in sterility or they are using one of the medically approved contraceptive methods. 10. Subject is covered by French health insurance. 11. Subject agrees to be registered in the national database of subjects participating in clinical research. Exclusion Criteria: 1. Any ongoing metabolic disease, hypertension, inflammatory disease, allergic conditions requiring chronic systemic medication, psychiatric disorder, gastrointestinal disorder, chronic pain, or neurological disorder diagnosed by a physician. 2. Known allergy or intolerance to any ingredients or potential allergens. 3. Pregnancy or breast-feeding at the screening visit or plan for pregnancy during the study. 4. Any antecedents or plan for digestive or dental surgery, general anaesthesia or any participation in another study with investigational or marketed products potentially affecting the gut microbiota. 5. Unable (or unwilling) to adhere to protocol requirements (based on investigator's judgement). 6. Subject with a special diet at the screening visit, or plan for such diet during the study. 7. Major changes in subject's dietary habits ≤ 4 weeks before the screening visit or plan for such major changes during the study including change in vitamin or mineral supplements use, but except for dietary restrictions related to the study. 8. Enhanced diet together with intense physical activity ≤ 4 weeks before the screening visit, plan for such a diet and training during the study, or plan for major changes in physical activity during the study. 9. Use ≤ 8 weeks before the screening visit or plan of use during the study of systemic medication that can affect the gastrointestinal function or plan of use during the study (if needed, incidental use of ≤ 4 tablets of paracetamol, non-steroidal anti-inflammatory drugs (NSAIDs) or aspirin per 2-week period is allowed). 10. Subject with excessive alcohol consumption, active smoker or quit active smoking less than 5 years ago before the screening visit. Not regularly smoking is allowed. 11. Drug abuse based on investigator's judgement. 12. Living in the same home as others already participating in the study and to concomitantly receive some study products. 13. Subject under guardianship, curatorship, person under judicial protection, family empowerment or future protection mandate. 14. Employees, family members or other relatives of employees of the participating centre or of Danone Global Research \& Innovation Center.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for A03 - digestive system are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Biofortis

    Paris, France

  • Biofortis

    Saint-Herblain, France

  • CEN

    Dijon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.